A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model.
A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model.
复制标题
DOI：
--
复制
发表时间：
2000-03
期刊：
影响因子：
11.2
通讯作者：
D. Needham;G. Anyarambhatla;G. Kong;M. Dewhirst
中科院分区：
文献类型：
--
作者：
D. Needham;G. Anyarambhatla;G. Kong;M. Dewhirst
目前药物递送（对于脂质体和其他载体）面临的最大挑战是仅在患病部位以可控的速率引发和产生包封药物的释放。我们的工作重点是开发一种新的热敏药物输送系统，特别是用于实体瘤的局部控制。我们在这里描述了一种新的脂质制剂，含有阿霉素，已优化为温和的高热温度（39摄氏度至40摄氏度），这是很容易实现的临床和快速释放时间的药物（几十秒）。发现这种新的脂质体与轻度热疗相结合，在减少人鳞状细胞癌异种移植物系（FaDu）中的肿瘤生长方面比游离药物或当前的脂质体制剂显著更有效，治疗后11天中有11天完全消退。
The single biggest challenge now facing drug delivery (for liposomes and indeed other carriers) is to initiate and produce release of the encapsulated drug only at the diseased site and at controllable rates. Our efforts have focused on developing a new thermal-sensitive drug delivery system, specifically for the local control of solid tumors. We describe here a new lipid formulation containing doxorubicin that has been optimized for both mild hyperthermic temperatures (39 degrees C to 40 degrees C) that are readily achievable in the clinic and rapid release times of drug (tens of seconds). This new liposome, in combination with mild hyperthermia, was found to be significantly more effective than free drug or current liposome formulations at reducing tumor growth in a human squamous cell carcinoma xenograft line (FaDu), producing 11 of 11 complete regressions lasting up to 60 days posttreatment.